SCHEMBL1850210

SCHEMBL1850210

COc1ccc(Cc2cc3cccc(-c4cccc(C(=O)O)c4)c3o2)cc1F

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR52 Q9Y2T5 1/20 0.49
MEP1B Q16820 2/20 0.46
RAB9A P51151 2/20 0.44
LMNA P02545 2/20 0.44
MAPK1 P28482 1/20 0.44
HTT P42858 1/20 0.44
MRGPRX4 Q96LA9 3/20 0.41
MEN1 O00255 1/20 0.40
NPC1 O15118 1/20 0.40
KMT2A Q03164 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
PTGER1 P34995 2/20 0.40
TDP1 Q9NUW8 2/20 0.40
CYP2C9 P11712 1/20 0.40
KDM4E B2RXH2 1/20 0.39
POLB P06746 1/20 0.39
MAPT P10636 1/20 0.39
PKM P14618 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
FFAR1 O14842 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3209922 0.91 GPR52 (0.49) GPR52RAB9ALMNAHTTMRGPRX4
SCHEMBL1849788 0.89 GPR52 (0.48) GPR52RAB9ANPC1SMN1; SMN2TDP1
SCHEMBL1855057 0.89 GPR52 (0.54) GPR52PTGER1CYP2C9PLA2G2AMAOA
SCHEMBL1862634 0.84 GPR52 (0.44) GPR52RAB9ANPC1SMN1; SMN2TDP1
SCHEMBL1852443 0.84 GPR52 (0.52) GPR52RAB9ANPC1PTGER1CYP2C9
SCHEMBL1849693 0.84 GPR52 (0.52) GPR52MEP1BRAB9AMRGPRX4SMN1; SMN2
SCHEMBL1849532 0.84 GPR52 (0.55) GPR52RAB9AMEN1NPC1KMT2A
SCHEMBL1854347 0.83 GPR52 (0.56) GPR52MRGPRX4PTGER1CYP2C9PLA2G2A
SCHEMBL1854648 0.80 GPR52 (0.47) GPR52RAB9AMEN1NPC1KMT2A
SCHEMBL1856476 0.80 GPR52 (0.51) GPR52RAB9AMEN1NPC1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2323978-A1 AMIDE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2011-05-25 EP disclosed
WO-2010018874-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-02-18 WO disclosed
US-20100041891-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-02-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041891-A1 AMIDE COMPOUND GPR52, GPR132, NR5A2 GPR52 1/4885MEP1B 2422/4885RAB9A 2891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.